फुफ्फुसाचा कर्करोग (non-small cell)
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
कुठे जायचं
या ट्रायलसाठी भारतातील 6 हॉस्पिटल्स रुग्णांना घेत आहेत.
रजिस्ट्री सारांश (तांत्रिक)
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) …
Sponsor: Pfizer
ClinicalTrials.gov वर NCT06758401
रजिस्ट्रीवर शेवटचे अपडेट 25 Sep 2026 · आमच्याकडून वाचले 20 Oct 2026